Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Post by Sonny7on Jul 24, 2020 8:40am
173 Views
Post# 31312938

No Mystery

No Mystery The news shows that Dr Anke Schulte, an “internationally acclaimed expert in diabetes and cell therapy regenerative medicine”, has been imbedded in the company and is the advisor in the newly created Sernova Advisory Board. Subsequent words to that message from the Doctors Toleikis and Schulte indicate that they were/are in a collaboration and have been for years as they describe the relationship. To me it’s all about as subtle as a real hard kick to the huevos. I believe Dr Schulte with her resume and experience Is very capable of acting as an advisor alright. I believe she will ultimately advise the CEO of Sanofi when to put some ink to the check book. 

If if they are showing USD$50B in the pockets, that would be enough to initiate an interesting starting point for an offer to purchase for the company, wouldn’t it? Doctor Witkowski must be showing some encouraging results. 
Bullboard Posts